Skip to main content
Premium Trial:

Request an Annual Quote

BD Reports 11-Percent Q2 Revenue Increase, 75-Percent Jump in Earnings

NEW YORK, July 22 (GenomeWeb News) - Becton Dickinson today reported a jump in revenues and income for the second quarter of 2005.

 

Revenues for the quarter were $1.38 billion, up 11 percent from $1.24 billion during the same period last year. BD Biosciences contributed $200 million to this, an 8-percent increase over the year-ago period. Research instrument and reagent growth contributed primarily to this growth, as well as discovery labware products. BD Biosciences' results do not include Clontech, which has been classified as a "discontinued operation." On July 1, BD said it will sell Clontech to Takara Bio of Japan.

 

Research and development costs increased to $67 million, from $58.5 million during the year-ago period.

 

BD's net income increased to $189.7 million, or $.73 per share, up almost 75 percent from $109.4 million, or $.41 per share, during last year's second quarter. Last year's results included a $100 million charge related to a litigation settlement with an undisclosed party in July 2004. BD said this charge reduced its prior-year net income by $63 million and EPS by $.24.

 

BD did not state its assets in its earnings report.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.